# Sao Tome and Principe

African Region









## I. Epidemiological profile

| Population (UN) | 2015 | % |
|---|---|---|
| High transmission (> 1 case per 1000 population) | 190,000 | 100 |
| Low transmission (0-1 cases per 1000 population) | 0 | - |
| Malaria-free (0 cases) | 0 | - |
| Total | 190,000 | |

**Parasites and vectors**

| | |
|---|---|
| Plasmodium species: | *P. falciparum (100%), P.vivax (0%)* |
| Major anopheles species: | *An. gambiae* |

| | | | |
|---|---|---|---|
| Reported confirmed cases (health facility): | 2,058 | Estimated cases: | 3,400 [2,600 ; 4,500] |
| Confirmed cases at community level: | - | | |
| Reported deaths: | 0 | Estimated deaths: | <100 |

## II. Intervention policies and strategies

| Intervention | Policies/strategies | Yes/No | Adopted |
|---|---|---|---|
| **ITN** | ITNs/ LLINs distributed free of charge | Yes | 2005 |
| | ITNs/ LLINs distributed to all age groups | Yes | 2008 |
| **IRS** | IRS is recommended | Yes | 2003 |
| | DDT is authorized for IRS | No | - |
| **Larval control** | Use of larval control recommended | Yes | 2004 |
| **IPT** | IPT used to prevent malaria during pregnancy | Yes | 2004 |
| **Diagnosis** | Patients of all ages should receive diagnostic test | Yes | 2001 |
| | Malaria diagnosis is free of charge in the public sector | Yes | 2008 |
| **Treatment** | ACT is free of charge for all ages in public sector | Yes | 2004 |
| | The sale of oral artemisinin-based monotherapies (oAMTs) | Is banned | 2004 |
| | Single dose of primaquine is used as gametocidal medicine for P. falciaprum | Yes | 2013 |
| | Primaquine is used for radical treatment of P. vivax | Yes | 2013 |
| | G6PD test is a requirement before treatment with primaquine | No | - |
| | Directly observed treatment with primaquine is undertaken | Yes | 2013 |
| | System for monitoring adverse reactions to antimalarials exists | No | 2004 |
| **Surveillance** | ACD for case investigation (reactive) | Yes | 2008 |
| | ACD of febrile cases at community level (pro-active) | Yes | 2006 |
| | Mass screening is undertaken | Yes | 2008 |
| | Uncomplicated P. falciparum cases routinely admitted | No | - |
| | Uncomplicated P. vivax cases routinely admitted | No | - |
| | Foci and case investigation undertaken | - | - |
| | Case reporting from private sector is mandatory | No | - |

| Antimalarial treatment policy | Medicine | Year adopted |
|---|---|---|
| First-line treatment of unconfirmed malaria | AS+AQ | 2004 |
| First-line treatment of P. falciparum | AS+AQ | 2004 |
| Treatment failure of P. falciparum | AL | 2004 |
| Treatment of severe malaria | QN | 2004 |
| Treatment of P. vivax | - | - |
| Dosage of Primaquine for radical treatment of P. vivax | | 0.25 mg/Kg (14 days) |
| Type pf RDT used | | P.f + P.v specific (Combo) |

**Therapeutic efficacy tests (clinical and parasitological failure, %)**

| Medicine | Year | Min | Median | Max | Follow-up | No of studies | Species |
|---|---|---|---|---|---|---|---|

**Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)**

| Year | Pyrethroid | DDT | Carbamate | Organophosphate | Species/complex tested |
|---|---|---|---|---|---|
| 2014–2015 | | | No | | An. gambiae s.s. |

## III. Financing

### Sources of financing




### Government expenditure by intervention in 2015 2015




Pie chart includes 100% of total expenditures

## IV. Coverage

### Coverage of ITN and IRS




Source: DHS 2009

With access to ITN (model)
With access to ITN (survey)
All ages who slept under ITN (survey)
At risk protected with IRS

### Cases tested and treated in public sector




Source: DHS 2009

Suspected cases tested
% <5 fever cases who had a finger/ heel stick
ACTs as % of all antimalarials received by <5 (survey)
Antimalarials distributed vs reported cases
ACTs distributed vs reported P. f. cases
Primaquine distributed vs reported P. v. cases

## V. Impact

### Cases treated




Source: DHS 2009

% fever cases <5 seeking treatment at public HF (survey)
Reporting completeness

### Test positivity




Parasite prevalence
Slide positivity rate
RDT positivity rate

### Confirmed malaria cases per 1000 and ABER




ABER (microscopy & RDT)
Cases (all species)
Cases (P. Vivax)

### Malaria admissions and deaths




Admissions (all species)
Admissions (P. vivax)
Deaths (all species)
Deaths (P.vivax)